Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Connect Biopharma Holdings Ltd (CNTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CNTB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.09% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 119.46M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 2 | Beta -0.08 | 52 Weeks Range 0.51 - 2.86 | Updated Date 08/15/2025 |
52 Weeks Range 0.51 - 2.86 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-13 | When - | Estimate -1.96 | Actual -0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -27966.67% |
Management Effectiveness
Return on Assets (TTM) -30.58% | Return on Equity (TTM) -49.45% |
Valuation
Trailing PE - | Forward PE 0.77 | Enterprise Value 48558270 | Price to Sales(TTM) 60.79 |
Enterprise Value 48558270 | Price to Sales(TTM) 60.79 | ||
Enterprise Value to Revenue 24.71 | Enterprise Value to EBITDA 0.19 | Shares Outstanding 55561100 | Shares Floating 14224625 |
Shares Outstanding 55561100 | Shares Floating 14224625 | ||
Percent Insiders 40.64 | Percent Institutions 44.74 |
Upturn AI SWOT
Connect Biopharma Holdings Ltd
Company Overview
History and Background
Connect Biopharma Holdings Ltd is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies to improve the lives of patients with chronic inflammatory diseases. Details on its founding year and specific milestones require further research as information is not readily available. The company focuses on T cell-driven diseases.
Core Business Areas
- T Cell-Driven Immunomodulation: Focuses on developing novel immunomodulatory therapies for T cell-driven inflammatory diseases. This is their primary business segment.
- Clinical Development: Conducting clinical trials for their lead product candidates, particularly CBP-201 (targeting IL-4Ru03b1) for atopic dermatitis and asthma.
Leadership and Structure
Connect Biopharma's leadership team includes key executives overseeing R&D, clinical development, and business operations. The specific structure is available on their corporate website or through public filings.
Top Products and Market Share
Key Offerings
- CBP-201 (Ilekizumab biosimilar candidate): An antibody targeting IL-4Ru03b1, being developed for atopic dermatitis and asthma. It competes with Dupixent (Sanofi/Regeneron). Market share data is not readily available without specific market research reports. Dupixent holds a significant market share in atopic dermatitis.
- CBP-174 (targeting peripheral T cell lymphoma): An antibody targeting peripheral T cell lymphoma and it's competitors are (Breyanzi, Adcetris, Folotyn, Istodax)
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Focus is on innovation, clinical trial success, and market access.
Positioning
Connect Biopharma is positioned as a clinical-stage company focused on innovative immunomodulatory therapies. Its competitive advantage lies in its specific targets and potentially differentiated clinical profiles.
Total Addressable Market (TAM)
The TAM for atopic dermatitis and asthma therapies is substantial, estimated in the billions of dollars globally. Connect Biopharma aims to capture a portion of this market with CBP-201, positioning itself as a potential competitor to established players like Sanofi and Regeneron.
Upturn SWOT Analysis
Strengths
- Targeting proven pathways (IL-4Ru03b1)
- Clinical-stage pipeline
- Experienced management team
Weaknesses
- Dependence on key product candidates
- High R&D expenditure
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent expiration
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Connect Biopharma is a smaller player competing with larger, established pharmaceutical companies. Success hinges on demonstrating superior efficacy or safety profiles in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst estimates would be needed for specific projections.
Recent Initiatives: Focusing on clinical trials for CBP-201 and CBP-174, exploring potential partnerships, and managing cash flow are key recent initiatives.
Summary
Connect Biopharma is a clinical-stage biopharmaceutical company with potential in the immunomodulatory therapy space. Their success depends on the outcomes of their clinical trials, especially for CBP-201. Competition is fierce and regulatory hurdles are significant, thus cash management and positive data is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Connect Biopharma Holdings Ltd
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-03-19 | CEO & Director Dr. Barry D. Quart Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://www.connectbiopharm.com |
Full time employees 62 | Website https://www.connectbiopharm.com | ||
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.